Product Code: RP-ID-10008247 |
Published Date: 21 Oct 2022 |
Region: Global |
Category: Healthcare & Pharmaceuticals |
Report ID: 10008247
Market Overview:
Global Orthobiologics Market Size, Growth, Opportunity and Forecast
"The global orthobiologics market is estimated to be valued at ~USD 7 billion by the end of 2021 and is expected to expand at a compound annual growth rate of ~8% during the forecast period 2022-2030. Due to the increase in accidents and obesity, the global increase in the number of orthopedic surgeries has mainly promoted the development of the industry. The growing elderly population is very sensitive to spine and other orthopedic diseases, which has also led to an increasing number of orthopedic surgeries.
According to a study published by the American College of Orthopaedic Surgeons in 2006, hip and knee replacements are expected to increase by 174% and 673%, respectively, in the next 20 years. This unprecedented increase in plastic surgery reflects the most likely need for plastic biologists to contain the aforementioned situation in the coming years.
In addition, the increased R&D investment and cooperation of leading biotechnology and medical device companies has led to the emergence of advanced orthopedic biology, which is believed to broaden the development basis of orthopedic biology. For example, as of May 2015, Bone Biologics Corp. is collaborating with the University of California to develop Nell-1, an orthopedic biological product that stimulates bone growth. The subsequent increase in R&D work has led to the expansion of a series of products being developed, which are expected to provide profitable growth opportunities for this vertical in the future.
PRODUCT INFORMATION:
In the product market segment, in 2020, viscose supplements accounted for the dominant share of the orthopedic biological market. A large part of this is due to the high adoption of these products, which is due to the wide availability of these products in diseases such as osteoarthritis, degenerative diseases and the unprecedented adoption of hip joints. The high adoption rate is believed to be the result of the benefits associated with sticky supplements. These benefits include better knee movement, less pain, less invasiveness, and fewer side effects. This is also considered to be a result of the high demand for minimally invasive surgery that has led to high acceptance by the patient population.
APPLICATION INFORMATION:
In 2020, spinal fusion accounted for more than 50% of the application field. The main part can be attributed to the continuous penetration of demineralized bone matrix, bone morphogenetic protein, autograft and allograft in spinal fusion surgery, because it can provide high bone stability and rapid bone healing, thereby improving long-term Spinal diseases.
Other benefits of orthopedic products in spinal fusion, such as faster stimulation of cells when bone formation begins and shorter hospitalization and visit times, are believed to account for more of their use. It is also thought that much of the biology of osteoporosis is due to the existence and costs associated with fusion products driving the existence and development of liability insurance.
CONCLUSION ON FINAL CONSUMPTION:
In 2020, hospitals accounted for the majority of final consumption. The increasing use of orthopedic products in a variety of spine and reconstructive surgeries in hospitals is a key factor in most services. In addition, intensive patient care and easy access to a wide range of orthopedic biology services in hospitals are expected to drive the growth of this service as well as lead to severe patient debilitation, frequent hospitalizations and high-dose care. .. The above actions have contributed to the contribution of this sector. .. also by supporting the infrastructure, accurate operational metrics can increase the efficiency of growth.
REGIONAL OVERVIEW :
North America held a large share of the global market in 2020. The share gained in this segment can be attributed to the presence of key players involved in improving quality assurance and implementing new development strategies for their products. In addition, the current cost of soft tissue treatment and fusion enhancing products will also significantly increase the share of the region, and the Asia Pacific region is expected to experience significant growth during the forecast period.
This increase is primarily due to increased physician awareness of the medical costs, disposable income and benefits of these products.
In addition, higher quality healthcare infrastructure should provide opportunities to increase the profitability of the region. Moreover, intensifying competition among the major players in this sector is one of the most important growth factors, along with the increasing product range in this sector. For example, in January 2016, Bioventus Durolane Injections launched hyaluronic acid as an injectable. Acidic joint - infusion therapy for osteoarthritis in Taiwan The introduction of this product will broaden the companys geographic reach and improve its impact on orthopedic products in the Asia Pacific region.
COMPETITIVE INFORMATION:
The key players in the north biotechnology market are Medtronic, Smith & Nephew plc, Stryker Corporation, Depuy Synthes and Inc. The company enzymes combine strategies to develop new products, collaborate, sell, merge and acquire. , and many repeat product reviews. In May 2016, NuVasive Inc. launched Putty Atrex, a next-generation biopharmaceutical technology based in the United States. This is an artificial bone graft called an autograft stent in posterior spine surgery. This product was introduced to expand the product line and gain a competitive edge over other market players.
SECTIONS PRESENTES IN THIS REPORT:
The report forecasts sales growth and provides analysis of industry trends in each sub-sector from 2022-2030. In this study, the Kenneth Research Orthopedic Market by Product, Use, End Use, Region: Global Overview Biological Orthopedic Products (Sales, USD 1 billion, 2022-2030) Allogeneic Bone Morphological Genetic Protein (DBM) BMP) Artificial Bone Replacement Cell Therapy Stem Cell Outlook Global Orthopedic Program (Sales, USD 1 Billion), 2022-2030 Global Orthopedic End-Use (Sales, $1 Billion, 2022-2030) Orthopedic Hospitals.
1. DepuySynthes (A Subsidiary of Johnson & Johnson)
2. Medtronic PLC.
3. Stryker Corporation
4. Zimmer Biomet Holdings, Inc.
5. Harvest Technologies Corporation (A Terumo Bct Company)
6. Globus Medical, Inc.
7. Orthofix International N.V.
8. RTI Surgical, Inc.
9. K2M Group Holdings, Inc.
10. Kuros Biosciences Ltd.
11. Bioventus LLC
12. Nuvasive, Inc.
13. Seaspine Holdings Corporation
14. Arthrex, Inc.
15. Xtant Medical Holdings, Inc.
Related Reports
Proof of Quality & Reliability
